Capricor Therapeutics, Inc. and Lonza announced that the companies have entered into an agreement for the development of CAP-1002, its leading clinical asset using allogeneic cardiosphere-derived cells (CDC) technology for the treatment of Duchenne Muscular Dystrophy (DMD) and complications arising from COVID-19. CAP-1002 completed the positive HOPE-2 phase 2 clinical trial and has been granted orphan drug designation by the FDA for the treatment of DMD. CAP-1002 also received FDA acceptance of its IND application for a phase 2 clinical trial of CAP-1002 in patients with COVID-19 in August 2020, as announced by Capricor.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.4 USD | -4.14% |
|
-8.52% | -10.02% |
Jul. 01 | Capricor Therapeutics Joins Russell 3000, Russell 2000 Indexes | MT |
Jul. 01 | Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell Small Cap Comp Value Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.02% | 141M | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- CAPR Stock
- News Capricor Therapeutics, Inc.
- Capricor Collaborates with Lonza for the Development of Cap-1002, Its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications